Bullish thesis on IMRN citing military/DoD backing, upcoming ProIBS launch, a Phase 2 trial for IMM-200, no dilution for a year, and a chart gap to fill.
IMRN — LONG The author argues IMRN is a pharmaceutical play with huge backing from the military and Department of Defense and ongoing research relationships with major US military institutions. Catalysts cited are the planned launch of ProIBS any day now (originally scheduled for Q4) and initiation of a Phase 2 clinical trial for IMM-200 in the first half of 2026. The author also notes no dilution with cash for the next year and a 52-week high of 2.50 versus a current 1.00 with a gap to fill on the daily chart.
IMRN is a pharmacuetical play with huge backing by the military and department of defense.
This Reddit post, published January 13, 2026, features u/Alpha1153 discussing IMRN. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Alpha1153 · Tickers: IMRN